News

xFOREST Therapeutics Announces Progress in Research Collaboration with Astellas Pharma

xFOREST Therapeutics (Headquartered in Kamigyo-ku, Kyoto, Japan; CEO: Shunichi Kashida; CTO: Kaoru Richard Komatsu; hereinafter “xFOREST”) today announced that the company has achieved a research deliverable as defined under its research collaboration agreement with Astellas Pharma Inc. (Headquartered in Chuo-ku, Tokyo, Japan; CEO: Naoki Okamura; hereinafter “Astellas”).

Under this collaboration, xFOREST is utilizing its proprietary RNA splicing–targeted drug discovery platform, “SpliceVerse,” to identify small molecules that modulate the splicing of specific genes. The first-stage research deliverable defined in the agreement has been completed and confirmed by both companies.

xFOREST will continue to advance its collaboration with Astellas to explore new possibilities in RNA-targeted drug discovery.